



Creating Innovative Therapies for Serious Human Diseases

Dr Deborah Rathjen
Chief Executive Officer & Managing Director

Safe Harbor Statement

Factors Affecting Future Performance

This presentation contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210, BNC105 and BNC101), its licensing agreement with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.


There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

Bionomics Overview

- **Global, clinical stage biopharmaceutical company leveraging our proprietary platform technologies ionX and MultiCore to discover and develop a deep pipeline of novel therapeutic candidates targeting ion channels**
- **Financials: Market Cap ~A\$210M; Cash at 30 June 2017 A\$42.87M; FY17 revenue and other income A\$28.25M; Operating loss after tax A\$6.75M (30 June 2017)**
- **Strategic partnership with Merck & Co., (MSD):**
 - Cognition therapeutic candidate entered clinical development and triggered US\$10M milestone payment in deal valued up to US\$506M in upfront, research and milestone payments plus additional royalties on net sales of licensed drugs
 - Merck & Co equity investment in October 2015, 4.5% ownership
- **Lead drug, BNC210, is a novel, orally-administered, first-in-class, modulator of $\alpha 7$ nicotinic acetylcholine receptor, in development for the treatment of anxiety and depression:**
 - Positive top line in Phase 2 clinical trial in Generalized Anxiety Disorder (GAD) patients reported 21 September 2016
 - Phase 2 trial in Post Traumatic Stress Disorder (PTSD) ongoing in Australia and US. Data anticipated H2, CY2018

Building an Australian Biotech: Time to Build Proprietary Platform Technologies, Discover & Develop CNS Therapeutic Candidates



Building an Australian Biotech: Need to Establish Global Collaborations

Partnership with Merck & Co in cognition generated US\$20M in upfront payment in 2014, research funding 2014+ and US\$10M first clinical milestone in February 2017 upon initiation of a Phase 1 clinical trial of an Alzheimer's Disease therapeutic candidate.

Deal valued up to US\$506M in upfront, research and milestone payments plus additional royalties on net sales of licensed drugs.



MERCK
PARTNERSHIP

- Validates ionX and MultiCore drug discovery platforms
- Value creation through strategic partnering business model
- Future success based revenue streams & royalties

Building an Australian Biotech: R&D Tax Incentive Provides Vital Funding for Clinical Trials

BNC210: Next Generation Therapeutic Candidate with Potential to Treat Anxiety Disorders, Co-morbid Anxiety and Stress & Trauma Related Disorders

- Clinical trials in Australia, France, UK and US
- Two US INDs for Anxiety Disorders and PTSD

Potential Competitive Advantages of BNC210*						
Drug	No sedation	No withdrawal syndrome	No memory impairment	Fast acting	No drug/drug interactions	Once-a-day dosing
BNC210	✓	✓	✓	✓	✓	✓
Valium and other BZD	✗	✗	✗	✓	✓	✗
Prozac and certain other SSRI/SNRI	✓	✗	✓	✗	✗	✓

Anxiety Treatments

- Dominated by benzodiazepines
- Associated with sedation, abuse liability, tolerance and cognitive disturbances
- Not recommended for long-term treatment

Depression Treatments

- SSRIs and SNRIs used to treat depression and anxiety
- Modest efficacy, late onset of action, discontinuation, weight gain, sexual dysfunction and increased thoughts of suicide in adolescents
- Many have black box warnings

Closing Comments

- Invest in and across the ecosystem: patient capital
- Companies need to use and become an active participant in the ecosystem: often unique capabilities in universities & research institutes and in other Australian companies

PharmAus17

Presented by Medicines Australia



Thank You

#PharmAus2017